Nigerian Content Hits 56% as Dorman Long Builds Local Capacity

Image
Nigerian Content Hits 56% as Dorman Long Builds Local Capacity

Lagos – October 16, 2026 -- Nigerian Content in the oil and gas sector reached 56% at the end of 2023, up from less than 5% in 2010, according to the Nigerian Content Development and Monitoring Board (NCDMB).

The board also reports that implementation of the Nigerian Oil and Gas Industry Content Development (NOGICD) Act has created more than 50,000 direct jobs. It has also kept over $8 billion in annual oil and gas expenditure within the Nigerian economy. The 2010 Local Content Act set the framework for greater participation by Nigerian companies and professionals.

NCDMB targets 70% Nigerian Content by 2027

The NCDMB's 10-Year Strategic Roadmap sets an ambition of 70% Nigerian Content by 2027. Dorman Long Engineering is presented as an example of how indigenous engineering, fabrication and talent development can support that target.

Nabsys Launches RepX to Screen 23 Repeat Expansion Loci in One Run

Image
Nabsys Launches RepX to Screen 23 Repeat Expansion Loci in One Run

Providence – October 16, 2026 -- Nabsys 2.0, LLC has released RepX, a cloud-based pipeline that can analyze up to 23 disease-associated repeat expansion loci in a single, low-cost run, according to the company.

RepX is available through the Nabsys Navigator cloud platform. It processes Electronic Genome Mapping (EGM) data generated on the OhmX Platform.

EGM reads single ultra-long DNA molecules without amplification or ligation

Repeat expansions are linked to numerous inherited disorders but remain difficult to characterize. EGM analyzes individual ultra-long DNA molecules without amplification or ligation, which avoids biases tied to those processes. Researchers can examine the distribution of expansion sizes and investigate repeat instability within each allele.

LG Takes SIGNATURE Laundry Line to High Point Market via NKBA

Image
LG Takes SIGNATURE Laundry Line to High Point Market via NKBA

High Point, N.C. – October 16, 2026 -- LG Electronics USA is bringing three LG SIGNATURE laundry and garment-care products into Broad Hall at High Point Market (October 17–26, 2026) through a partnership with the National Kitchen & Bath Association (NKBA), targeting interior designers, architects and specifiers.

The activation, titled "Designer Closet and Hidden Laundry," is designed in collaboration with Barbour Spangle Design. It positions garment care inside custom dressing rooms, luxury closets and residential wellness spaces rather than in a conventional laundry room. LG cites OpenBrand MarketShare data (AHAM Core 6, 2024-2026) in describing itself as the number one appliance brand in the US.

Three LG SIGNATURE products anchor the Broad Hall display

The showcase features the following models:

Tercera 30 Adds Anthropic, OpenAI, Palantir as Market Anchors

CHICAGO – October 16, 2026 -- Eleven vendors are new or returning on Tercera's fifth annual Tercera 30 ranking, the most turnover the growth equity firm has recorded in its Market Anchors category, as Anthropic, OpenAI and Palantir join that group for the first time.

The 2026-2027 list ranks the software and AI vendors and partner ecosystems with the greatest services growth potential for IT services firms. Tercera, an investment and advisory firm for AI and technology service firms, said the list reflects the shift across IT services in the AI era.

Single-vendor focus halves to 5% of IT services firms in Tercera survey

In Tercera's July 2026 survey of 378 technology services leaders, only 5% of firms focused on a single software partner, down from 10% a year earlier. Firms are moving away from single-vendor platform implementations. They now orchestrate data, systems and agents around domain processes and defined business outcomes.

Lockheed Martin Delivers First C-130J-30 for Navy's E-130J TACAMO

Image
Lockheed Martin Delivers First C-130J-30 for Navy's E-130J TACAMO

Marietta – October 16, 2026 -- Lockheed Martin (NYSE:LMT) delivered the first C-130J-30 Super Hercules for the U.S. Navy's Take Charge and Move Out (TACAMO) mission on Oct. 15 at its Marietta, Georgia, facility. The aircraft will be modified into the E-130J Phoenix II, the Navy's next-generation airborne nuclear command-and-control platform.

Northrop Grumman to complete the E-130J conversion as mission systems integrator

The airframe will be transferred to Northrop Grumman, the mission systems integrator. The E-130J TACAMO industry team will then complete the conversion before the aircraft enters service as the E-130J Phoenix II.

Capt. Roger Davis, program manager for Airborne Strategic Command, Control and Communications (PMA-271), said the Navy now moves into mission systems integration. He described the delivered airframe as the structural and performance backbone for the mission.

Health In Tech Sets Nov. 10 Virtual Annual Meeting for Stockholders

Image
Health In Tech Sets Nov. 10 Virtual Annual Meeting for Stockholders

Stuart, Fla. – October 16, 2026 -- Health In Tech, Inc. (Nasdaq: HIT) will hold its 2026 Annual Meeting of Stockholders on Tuesday, November 10, 2026, at 10:00 AM ET via live virtual webcast.

Stockholders of record as of Sept. 18 can vote and submit questions electronically

Holders of Health In Tech stock at the close of business on September 18, 2026, the Record Date, are eligible to vote their shares electronically during the meeting. They can also submit questions live during the session.

Eligible stockholders join through the company's designated virtual meeting portal at cleartrustonline.com/HIT.

Guests can attend in listen-only mode without a control number

Non-stockholders may access the 2026 Annual Meeting in listen-only mode. Guests do not need a control number to join.

FDA Approves UCB's ZILBRYSQ Autoinjector for gMG; Launch Set for Q1 2027

Image
FDA Approves UCB's ZILBRYSQ Autoinjector for gMG; Launch Set for Q1 2027

Atlanta – October 16, 2026 -- The U.S. Food and Drug Administration (FDA) has approved a once-daily autoinjector for UCB's ZILBRYSQ (zilucoplan), with complete dose delivery in 99.8% of 449 administrations, UCB said. Commercial availability is expected in Q1 2027.

The device is cleared for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. UCB (Euronext Brussels: UCB) describes ZILBRYSQ as the first and only macrocyclic peptide C5 inhibitor approved as a self-administered, once-daily subcutaneous autoinjector for gMG in the U.S.

Autoinjector adds a second self-administration route alongside the prefilled syringe

Before this approval, ZILBRYSQ was available only as a self-administered prefilled syringe (PFS). The autoinjector automatically delivers a pre-defined dose when activated against the skin. Patients or their care partners now have two portable options.

Attilio Names Buck Institute CEO Eric Verdin Co-Chairman

Image
Attilio Names Buck Institute CEO Eric Verdin Co-Chairman

St. Petersburg, Florida – October 16, 2026 -- Attilio, a longevity platform launched in September 2026, has appointed Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging, as Co-Chairman. The company prices the Dr. Verdin Baseline Assessment(TM), built on his research, at $2,500 per member.

Verdin brings Buck Institute research access to Attilio's care model

The Buck Institute describes itself as the first independent biomedical research institute focused solely on aging and age-related disease. Founded in Novato, California, it helped establish the field known as geroscience.

TORL BioTherapeutics Names New CFO and CMO Ahead of Late-Stage Push

Image
TORL BioTherapeutics Names New CFO and CMO Ahead of Late-Stage Push

Los Angeles – October 16, 2026 -- TORL BioTherapeutics has appointed Sandip Kapadia as Chief Financial Officer, a executive who has raised more than $2 billion in public capital for emerging biotechnology companies, and Eric Sievers, M.D., as Chief Medical Officer, completing a year-long expansion of its leadership team.

TORL prepares lead antibody-drug conjugate for late-stage development

The clinical-stage oncology company is advancing its antibody-based portfolio toward late-stage development and potential commercialization. Its lead asset, ixotatug vedotin (Ixo-V), is being evaluated in platinum-resistant ovarian cancer and other cancers that express CLDN6, including germ cell tumors, and in various combinations. Ixo-V has FDA Fast Track designation.

TORL describes Ixo-V as the first and only antibody-drug conjugate (ADC) that selectively targets Claudin 6 (CLDN6) using a proven monomethyl auristatin E (MMAE) linker-payload construct.

NG Energy's Aruchara-6 Well Lifts Maria Conchita Gas Output to 23 MMcf/d

Image
NG Energy's Aruchara-6 Well Lifts Maria Conchita Gas Output to 23 MMcf/d

Bogotá – October 16, 2026 -- NG Energy International Corp. expects total gross production at its Maria Conchita block in Colombia to rise to 23.0 MMcf/d from 16.0 MMcf/d after the Aruchara-6 well tested at up to 8.7 MMcf/d gross and entered production.

Aruchara-6 flows at 8.7 MMcf/d gross through the central processing facility

The well was drilled to a total depth of 9,352 feet and hit the H1 target as designed. It also passed through the H2, H3, H4, H5 and H6 zones, all of which showed gas at surface and on wireline logs. During initial flow testing through the central processing facility (CPF), Aruchara-6 produced up to 8.7 MMcf/d gross (6.96 MMcf/d net) on a 30/64 choke at an average tubing head pressure of 780 psi.